Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) is hosting an exclusive live investor webinar and Q&A session on October 29, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Motti Farbstein and Executive Chairperson and CSO Dr. Pnina Fishman, who will discuss the company's development pipeline and upcoming milestones.

Can-Fite has multiple out-licensing deals with potential milestone payments exceeding $450 million, having already received $20 million in upfront and milestone payments. The company's advanced-stage assets target unmet medical needs in markets valued at over $70 billion. Investors can register for the free webinar and submit questions in advance or during the live event.

Positive

• Multiple out-licensing deals with potential milestone payments exceeding $450 million
• Already received $20 million in upfront and milestone payments
• Advanced-stage assets targeting markets valued at over $70 billion
• Potential commercialization of innovative therapies

Negative

• None.

RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on October 29, 2024, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Can-Fite Chief Executive Officer Motti Farbstein and Executive Chairperson and Chief Scientific Officer Dr. Pnina Fishman, who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential milestone payments totaling over $450 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite  believes it is well positioned for the potential commercialization of its innovative therapies.

To register for the free webinar, please visit:

https://redchip.zoom.us/webinar/register/WN_3UZ8u9huRsmIbV216KrdwA#/registration

Questions can be pre-submitted to CANF@redchip.com or online during the live event.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

Dave Gentry
RedChip Companies, Inc.
CANF@redchip.com   
1-407-644-4256

FAQ

When is Can-Fite BioPharma (CANF) hosting its live investor webinar?

Can-Fite BioPharma (CANF) is hosting its live investor webinar on October 29, 2024, at 4:15 p.m. ET.

Who will be presenting at Can-Fite BioPharma's (CANF) investor webinar?

Can-Fite BioPharma's (CANF) investor webinar will feature CEO Motti Farbstein and Executive Chairperson and CSO Dr. Pnina Fishman.

What is the total potential value of Can-Fite BioPharma's (CANF) out-licensing deals?

Can-Fite BioPharma's (CANF) out-licensing deals have potential milestone payments totaling over $450 million.

How much has Can-Fite BioPharma (CANF) already received in upfront and milestone payments?

Can-Fite BioPharma (CANF) has already received $20 million in upfront and milestone payments.